Trial reportBreast cancer research and treatment2012
A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors.
Trial report in Breast cancer research and treatment, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Use of Gabapentin in the Treatment of Substance Use and Psychiatric Disorders: A Systematic Review.Frontiers in psychiatry · 2019Pooled it
- Gabapentin misuse, abuse and diversion: a systematic review.Addiction (Abingdon, England) · 2016Pooled it
- Effect of Gabapentin Pretreatment on Hyperalgesia in Older Patients Undergoing Sequential Bilateral Cataract Surgery: A Prospective, Randomized Controlled Trial.Journal of clinical medicine · 2026Article
- Management of fragile X-associated tremor ataxia syndrome: a review for clinicians.Frontiers in neurology · 2026Review
- Management of vasomotor symptoms in cancer patients.The oncologist · 2025Review
- Molecular relation between biological stress and carcinogenesis.Molecular biology reports · 2022Review
- Article
- α2δ-1-Dependent NMDA Receptor Activity in the Hypothalamus Is an Effector of Genetic-Environment Interactions That Drive Persistent Hypertension.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2021Article
- A Novel Peripheral Action of PICK1 Inhibition in Inflammatory Pain.Frontiers in cellular neuroscience · 2021Article
- Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology.Frontiers in psychiatry · 2020Review
- A qualitative analysis of gabapentin misuse and diversion among people who use drugs in Appalachian Kentucky.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2018Article
- Gabapentin for the treatment of alcohol use disorder.Expert opinion on investigational drugs · 2018Review
- Anxiety and Depression in Cancer Survivors.The Medical clinics of North America · 2017Review
- Anxiety Disorders Among Women: A Female Lifespan Approach.Focus (American Psychiatric Publishing) · 2017Article
- Anxiety as a risk factor for menopausal hot flashes: evidence from the Penn Ovarian Aging cohort.Menopause (New York, N.Y.) · 2016Article
- Bee pollen and honey for the alleviation of hot flushes and other menopausal symptoms in breast cancer patients.Molecular and clinical oncology · 2015Article
- Psychopharmacology in cancer.Current psychiatry reports · 2015Review
- Gabapentin Therapy in Psychiatric Disorders: A Systematic Review.The primary care companion for CNS disorders · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Gabapentin is used for the treatment of hot flashes and neuropathic pain in breast cancer survivors, and is commonly used off-label for the treatment of anxiety. Yet, clinical trial evidence to support the use of gabapentin for anxiety symptoms is lacking. In a randomized, double-blinded controlled trial we compared 300 mg gabapentin versus 900 mg gabapentin versus placebo. Subjects were 420 breast cancer patients who had completed all chemotherapy cycles. Anxiety traits and current (state) anxiety were measured using the Speilberger Strait-Trait Anxiety Inventory at baseline, 4 and 8 weeks. Pain was measured at baseline using a 10-point scale. Analyses included analysis of covariance and ordinary least squares regression. At 4 weeks, state anxiety change scores were significantly better for gabapentin 300 and 900 mg (p = 0.005) compared to placebo. The magnitude of improvement was proportional to baseline state anxiety. At 8 weeks, the anxiolytic effects of gabapentin compared to placebo persisted (p < 0.005). We found no significant interactions. The lower dose (300 mg) was associated with the best treatment outcomes for all patients except those with the highest baseline anxiety. Given its similar pharmacology, efficacy in the treatment of hot flashes, and low cost, gabapentin may provide a low cost and parsimonious alternative treatment choice for breast cancer survivors presenting in primary care practices with anxiety symptoms. Gabapentin is effective for hot flashes, and, therefore, may provide therapeutic benefit for both anxiety and hot flashes at a generic drug price. For patients reluctant to take a controlled substance, such as a benzodiazepine, gabapentin may offer an alternative therapy. Similarly, patients with a history of substance use may benefit from gabapentin without risk of addiction or abuse. For cancer survivors experiencing both hot flashes and anxiety, gabapentin may provide a single effective treatment for both and is an alternative therapy for anxiety for patients unwilling to take a benzodiazepine or those with a history of substance use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.